6 completed, 3 terminated, 2 unknown, 1 withdrawn. 12 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Terminated 3, Unknown 2, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Systemic Mastocytosis: new trials by email Literature Review of Systemic Mastocytosis trials Research Report on Systemic Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Treatment of Indolent Systemic Mastocytosis With PA101 PA101, Placebo - Mastocytosis, Systemic Mastocytosis | Phase 2 | Completed | Patara Pharma | 41 | 2015-06-01 | 2016-09-29 |
| Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Terminated | Jason Robert Gotlib | 4 | 2015-03-01 | 2018-09-20 |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Completed | Jason Robert Gotlib | 10 | 2013-09-01 | 2019-01-29 |
| Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Cladribine and pegylated interpheron alpha-2a - Systemic Mastocytosis | Phase 2 / Phase 3 | Unknown | Hospital Virgen de la Salud | 10 | 2012-05-01 | 2016-08-29 |
| Evaluation of Response of Dasatinib to Treat Mastocytosis Dasatinib - Systemic Mastocytosis | Phase 2 | Unknown | Federico II University | 30 | 2009-11-01 | 2009-09-18 |
| Obatoclax for Systemic Mastocytosis Obatoclax Mesylate - Leukemia, Systemic Mastocytosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2009-06-01 | 2011-11-04 |
| Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis RAD001 (Everolimus) - Systemic Mastocytosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 10 | 2007-04-01 | 2026-07-06 |
| A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Nilotinib - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 507 | 2005-04-01 | 2021-06-29 |
| Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes imatinib mesylate - Hypereosinophilic Syndrome, Systemic Mastocytosis | Phase 2 | Completed | Novartis Pharmaceuticals | 38 | 2004-09-01 | 2017-02-23 |
| Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Ontak (Denileukin Diftitox) - Leukemia, Systemic Mastocytosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 8 | 2004-07-01 | 2012-02-08 |
Mastocytosis, Systemic (12) · Leukemia, Mast-Cell (4) · Hypereosinophilic Syndrome (2) · Leukemia (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Mastocytosis (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Dermatofibrosarcoma (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Hairy Cell (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1)
Immune System Diseases (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Neoplasms, Connective Tissue (12) · Neoplasms, Connective and Soft Tissue (12) · Mast Cell Activation Disorders (11) · Mastocytosis (10) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Leukemia, Myeloid (7) · Leukemia (6) · Bone Marrow Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Leukemia, Myeloid, Acute (3)
Brentuximab Vedotin (1) · Cladribine (1) · Dasatinib (1) · Everolimus (1) · Imatinib Mesylate (1) · denileukin diftitox (1) · ibrutinib (1) · nilotinib (1) · obatoclax (1)
M.D. Anderson Cancer Center (3) · Jason Robert Gotlib (2) · Novartis Pharmaceuticals (2) · City of Hope Medical Center (1) · Federico II University (1) · GT Biopharma, Inc. (1) · Hospital Virgen de la Salud (1) · Patara Pharma (1)
United States (7) · Italy (3) · Spain (3) · Australia (2) · France (2) · Germany (2) · Netherlands (2) · Austria (1) · Belgium (1) · Canada (1) · Denmark (1) · Finland (1) · Hong Kong (1) · New Zealand (1) · Norway (1)
Srdan Verstovsek, MD (3) · Jason Gotlib (2) · Frank Siebenhaar, MD (1) · Ibrahim Aldoss, MD (1) · Luis Escribano, MD, PhD (1) · Mark B Juckett, MD (1) · Massimo Triggiani, MD (1)
PMID 16775235, PMID 17715389, PMID 21098399, PMID 23547655, PMID 24057647, PMID 26002753, PMID 31350306
P30CA124435 (1)